ATE293690T1 - Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie - Google Patents

Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie

Info

Publication number
ATE293690T1
ATE293690T1 AT99972219T AT99972219T ATE293690T1 AT E293690 T1 ATE293690 T1 AT E293690T1 AT 99972219 T AT99972219 T AT 99972219T AT 99972219 T AT99972219 T AT 99972219T AT E293690 T1 ATE293690 T1 AT E293690T1
Authority
AT
Austria
Prior art keywords
immunotherapy
associated antigen
cancer
taa
tumours
Prior art date
Application number
AT99972219T
Other languages
English (en)
Inventor
Miles William Carroll
Kevin Alan Myers
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293690(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9825303.2A external-priority patent/GB9825303D0/en
Priority claimed from GBGB9901739.4A external-priority patent/GB9901739D0/en
Priority claimed from GBGB9917995.4A external-priority patent/GB9917995D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE293690T1 publication Critical patent/ATE293690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT99972219T 1998-11-18 1999-11-18 Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie ATE293690T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9825303.2A GB9825303D0 (en) 1998-11-18 1998-11-18 Vector
GBGB9901739.4A GB9901739D0 (en) 1999-01-27 1999-01-27 Polypeptide
GBGB9917995.4A GB9917995D0 (en) 1999-07-30 1999-07-30 Polypeptide
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy

Publications (1)

Publication Number Publication Date
ATE293690T1 true ATE293690T1 (de) 2005-05-15

Family

ID=27269555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972219T ATE293690T1 (de) 1998-11-18 1999-11-18 Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie

Country Status (10)

Country Link
EP (4) EP1036091B2 (de)
JP (1) JP4907767B2 (de)
KR (1) KR20010084935A (de)
CN (1) CN1298851C (de)
AT (1) ATE293690T1 (de)
AU (1) AU766954B2 (de)
CA (1) CA2351622A1 (de)
DE (1) DE69924826T8 (de)
GB (1) GB2347932B (de)
WO (1) WO2000029428A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036486A2 (en) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
DE60040555D1 (de) * 1999-11-18 2008-11-27 Oxford Biomedica Ltd Küle
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
WO2002038612A2 (en) * 2000-11-13 2002-05-16 Oxford Biomedica (Uk) Limited Canine and feline tumour-associated antigen 5t4
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
CA2434546C (en) * 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
GB0102947D0 (en) * 2001-02-06 2001-03-21 Oxford Biomedica Ltd Method
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
EP2345665A3 (de) 2001-12-04 2012-02-15 Bavarian Nordic A/S Impfstoff aus der NS1-Untereinheit eines Flavivirus
WO2003064665A2 (en) 2002-02-01 2003-08-07 Oxford Biomedica (Uk) Limited Viral vector
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
EP1420822B2 (de) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
SI1434858T2 (sl) 2002-09-05 2019-05-31 Bavarian Nordic A/S Postopek za pomnoževanje poksvirusa v razmerah brez seruma
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
JP2007527692A (ja) 2003-05-21 2007-10-04 アレス トレイディング ソシエテ アノニム Ｔｎｆ様分泌タンパク質
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
ATE525401T1 (de) 2005-05-13 2011-10-15 Oxford Biomedica Ltd Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2007106744A2 (en) 2006-03-10 2007-09-20 Wyeth Anti-5t4 antibodies and uses thereof
WO2008045563A2 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
ES2627274T3 (es) 2006-10-23 2017-07-27 Medical Research Council Polimerasa
ES2726850T3 (es) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco
KR102355745B1 (ko) 2013-10-11 2022-01-26 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7277388B2 (ja) 2017-03-15 2023-05-18 オックスフォード バイオメディカ（ユーケー）リミテッド 方法
EP3717021A1 (de) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepin-antikörper-konjugate
EP3727463A1 (de) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepin-antikörper-konjugate
EP3873534A1 (de) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cystein-modifizierte antikörper-wirkstoff-konjugate mit peptidhaltigen linkern
CN120098072B (zh) * 2025-03-06 2025-11-04 杭州佰倍优生物科技有限公司 一种改善脑损伤的活性肽及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002077A1 (en) 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
AU3353989A (en) * 1988-03-04 1989-09-22 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
DE69133511T2 (de) 1990-08-13 2006-09-28 Isis Pharmaceuticals, Inc., Carlsbad Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
WO1998004727A1 (en) * 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
IL134897A0 (en) 1997-09-23 2001-05-20 Oxford Biomedica Ltd Expression of genes in hematopoietic stem cells in ischemic conditions

Also Published As

Publication number Publication date
CA2351622A1 (en) 2000-05-25
AU766954B2 (en) 2003-10-30
JP2002530060A (ja) 2002-09-17
EP2042598A1 (de) 2009-04-01
CN1333829A (zh) 2002-01-30
WO2000029428A3 (en) 2000-11-09
DE69924826T2 (de) 2006-02-23
EP1036091A1 (de) 2000-09-20
DE69924826T3 (de) 2008-05-29
EP1160323A1 (de) 2001-12-05
GB0014986D0 (en) 2000-08-09
EP1036091B2 (de) 2008-03-26
GB2347932B (en) 2003-05-07
JP4907767B2 (ja) 2012-04-04
AU1394900A (en) 2000-06-05
WO2000029428A2 (en) 2000-05-25
DE69924826T8 (de) 2008-09-25
CN1298851C (zh) 2007-02-07
EP1152060A1 (de) 2001-11-07
DE69924826D1 (de) 2005-05-25
EP1036091B1 (de) 2005-04-20
KR20010084935A (ko) 2001-09-07
EP1152060B1 (de) 2015-04-15
GB2347932A (en) 2000-09-20

Similar Documents

Publication Publication Date Title
ATE293690T1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
IL145813A0 (en) SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ1
MX343744B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
IL138075A0 (en) Vaccines, immunotherapeutics and methods for using the same
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
WO2021252620A3 (en) Dna encoded antibodies for use against sars-cov-2
EP1126872A4 (de) KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGEN EINSCHLIESSLICH hERT
ATE414146T1 (de) Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav- vektoren mit hohem titer
EP1536006A4 (de) Krebsantigene und deren nutzung
MXPA01008605A (es) Proteina de enlace del antigeno goodpasture.
WO2003085087A8 (en) Modified cea nucleic acid and expression vectors
IL156041A0 (en) Nucleic acid adjuvants
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
IL139683A0 (en) Composition for the induction of a tumour-specific immune response, methods for its production and use of the composition for the treatment of neoplasia
WO2005035773A8 (en) Modified cea /b7 vector
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
EA200000618A1 (ru) Вакцина для иммунизации позвоночных против заболеваний, вызываемых патогеном, вакцина для профилактики или лечения позвоночного от бруцеллеза, аттенюированный или авирулентный вариант штамма в. abortus rb51, способ профилактики или лечения позвоночного при риске заболевания или страдающего от патогенного микроорганизма (варианты), способ профилактики или лечения позвоночного при риске заболевания или страдающего от бруцеллеза
AU2002336244A1 (en) Trp2 isoform trp2-6b containing hla-a2-restricted epitopes
WO2005068640A3 (en) Modified ksa and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1036091

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1036091

Country of ref document: EP